Shak­ing up Chi­na's PD-(L)1 re­im­burse­ment land­scape, In­novent, Eli Lil­ly earn cov­et­ed spot on na­tion­al cov­er­age

Last week
China
Pharma

Bak­er Bros. places a $250M bet on a po­ten­tial ri­val to Re­gen­eron and No­var­tis — with a $1B-plus pay­off on the line

Last week
Deals

No­var­tis, Ver­tex out­line big gene ther­a­py plans — fu­el­ing a glob­al boom

Last week
Cell/Gene Tx

In­sid­er ac­count of UCB’s $2.1B deal to buy Ra Phar­ma spot­lights a dis­ci­plined M&A strat­e­gy — and $120M wind­fall for ex­ecs

Last week
R&D

Ko­re­an biotech’s shares soar for a 'best of ES­MO' award it nev­er re­ceived

Last week
R&D

Feds add fraud charges to the mul­ti­tude of ac­cu­sa­tions made against for­mer MiMedx ex­ecs

2 weeks ago
Pharma

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

2 weeks ago
R&D

Make that 2 new sick­le cell dis­ease block­buster hope­fuls OK’d by the FDA in just a few days

3 weeks ago
R&D
Regulatory

‘Break­through’ blad­der can­cer drug spin­out gets $570M to back launch of a new gene ther­a­py in the US

3 weeks ago
Deals
R&D

Har­vard con­sor­tium blue­prints $50M cell and gene ther­a­py cen­ter — but can they ac­tu­al­ly fos­ter low­er drug prices?

3 weeks ago
R&D

Ac­quis­i­tive No­var­tis bags PC­SK9 play­er Med­Co for $9.7B, set­ting up a flank at­tack on Sanofi, Re­gen­eron and Am­gen

3 weeks ago
Deals
R&D

Cel­gene R&D vet jumps to biotech: 'It’s about short­en­ing the cy­cle'; No­var­tis ex­o­dus con­tin­ues as William Chou takes the helm at Aru­vant

3 weeks ago
Peer Review

Bio­gen's Al San­drock says the FDA needs to ap­prove their con­tro­ver­sial Alzheimer's drug — now

3 weeks ago
Bioregnum
R&D

Ahead of strate­gic up­date, new Sanofi CEO mulls op­tions for con­sumer health­care arm — re­ports

3 weeks ago
Deals
Pharma

The triple crown in biotech: An all-or-noth­ing bet on an FDA ap­proval of 3 drugs over 16 months starts to­day

3 weeks ago
R&D

Make that 2 ap­proved RNAi drugs at Al­ny­lam af­ter the FDA of­fers a speedy OK on ul­tra-rare dis­ease drug

3 weeks ago
R&D

Eli Lil­ly touts $400M man­u­fac­tur­ing ex­pan­sion, 100 new jobs to much fan­fare in In­di­anapo­lis — even though it's been chop­ping staff

3 weeks ago
Pharma

Lon­don's bio­phar­ma-fo­cused GHO Cap­i­tal Part­ners claims close of largest-ever Eu­ro­pean fund

3 weeks ago
Venture

Am­gen chops 172 more staffers in R&D, op­er­a­tions and sales amid neu­ro­science ex­it, rev­enue down­turn

3 weeks ago
People

Ab­b­Vie lines up a new pre­clin­i­cal R&D al­liance with the deal­mak­ers at nat­ur­al killer play­er Drag­on­fly

3 weeks ago
R&D

No­var­tis is eye­ing a multi­bil­lion-dol­lar Med­Co buy­out as Jer­sey biotech nears NDA — re­ports

3 weeks ago
R&D

In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

3 weeks ago
Cell/Gene Tx
R&D

Alk­er­mes forges $950M biotech buy­out deal in a bold bet on an ear­ly-stage CNS drug plat­form

4 weeks ago
R&D

Af­ter a late-stage miss, No­var­tis touts an­oth­er En­tresto analy­sis to con­vince the FDA to ex­pand the block­buster's la­bel

4 weeks ago
Pharma
R&D
First page Previous page 12345 Next page Last page